Skip to main content
. 2022 Jan 19;23(3):1063. doi: 10.3390/ijms23031063

Figure 2.

Figure 2

JG-98 analogs suppress the viability of drug-resistant TT and MZ-CRC-1 cells. (A) IC50 analysis in vandetanib- and cabozantinib-resistant TT cells (TT/rV and TT/rC, respectively) treated with indicated inhibitors for 72 h. (B) IC50 analysis in vandetanib- and cabozantinib-resistant MZ-CRC-1 cells (MZ/rV and MZ/rC, respectively) treated with indicated inhibitors for 72 h. Data (mean ± SEM, n = 3) are expressed as the percentage of vehicle-treated control. Cell viability was determined by MTT assay.